Evidence map›Paper›PMID 36408542›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2022

Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases.

Luan D Vu, Shonta Wallace, Anh Tq Phan, Rebecca C Christofferson, Erik Turner, Sean Parker, Karen Elkind-Hirsch, Darrell Landry, Austin Stansbury, Rebecca Rose and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Luan D VuDepartment of Biological Sciences, Louisiana State University and Pennington Biomedical Research Center, Baton Rouge, LA 70803, USA.ORCID 0000-0001-8493-1811
Shonta WallaceWoman's Hospital, Baton Rouge, LA 70817, USA.
Anh Tq PhanDepartment of Biological Sciences, Louisiana State University and Pennington Biomedical Research Center, Baton Rouge, LA 70803, USA.
Rebecca C ChristoffersonDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Erik TurnerDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.ORCID 0000-0003-3984-2419
Sean ParkerWoman's Hospital, Baton Rouge, LA 70817, USA.
Karen Elkind-HirschWoman's Hospital, Baton Rouge, LA 70817, USA.ORCID 0000-0003-3577-4009
Darrell LandryWoman's Hospital, Baton Rouge, LA 70817, USA.
Austin StansburyWoman's Hospital, Baton Rouge, LA 70817, USA.
Rebecca RoseBioInfoExperts, Thibodaux, LA 70301, USA.
David J NolanBioInfoExperts, Thibodaux, LA 70301, USA.
Susanna L LamersBioInfoExperts, Thibodaux, LA 70301, USA.
Michael HireziLouisiana Health Sciences Center New Orleans, New Orleans, LA 70112, USA.
Beverly OgdenWoman's Hospital, Baton Rouge, LA 70817, USA.
Stephania A CormierDepartment of Biological Sciences, Louisiana State University and Pennington Biomedical Research Center, Baton Rouge, LA 70803, USA.ORCID 0000-0002-6050-6172
Woman's Hospital · USPennington Biomedical Research Center · USLouisiana State University · USLouisiana State University Health Sciences Center New Orleans · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the risk factors for breakthrough coronavirus disease 2019 (COVID-19) (BC19) is critical to inform policy. Herein, we assessed Delta (Lineage B.1.617.2) variant-specific effectiveness of the BNT162b2 (Pfizer) vaccine and characterized Delta-driven BC19 cases (fully vaccinated individuals who get infected) with known-time-since-vaccination. In this longitudinal prospective study (January 21-October 30, 2021), 90 naïve and 15 convalescent individuals were enrolled at the initiation of vaccination. Samples from 27 unvaccinated individuals with previous laboratory-confirmed COVID-19 diagnosis were collected at a single time point. Longitudinal serology profile (antibodies against severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] S and N proteins) and live-virus-based neutralization capacities were assessed while controlling for age. Sex, age, history of reactions to the COVID-19 vaccine, and viral neutralization capacities were identified as significant risk factors for breakthrough COVID-19. At 8 months postvaccination, male sex, individuals ⩾65 years of age, and individuals who experienced noticeable side effects with the COVID-19 vaccine were at 5.47 (

Indexed as

COVID-19COVID-19 VaccinesAntibodiesAntibody FormationBNT162 VaccineCOVID-19 TestingHumansMaleProspective StudiesSARS-CoV-2AntibodiesBNT162 VaccineCOVID-19 Vaccinesand N proteinboosterCOVID-19 breakthroughSARS-CoV-2

Identifiers

PMID36408542
PMCPMC9679329
OpenAlexW4309508827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.